cyrilzakka/clinical-trials huggingface dataset:
Evaluation Of Effect of Axial Length on Cup-To-Disc Ratio Among Non- Glaucomatous Hypertensive Patients

This observational cross-sectional study aims to compare the effect of axial length on the cup-to-disc ratio in non-glaucomatous hypertensive patients. Data will be collected from Khursheed Begum Eye Hospital and LRBT Hospital, with a sample size of 104 participants. A purposive sampling technique will be used.

Patients aged 18-70 years with systemic hypertension for at least one year and normal intraocular pressure will be included. Exclusion criteria include glaucoma, high myopia, hyperopia, ocular surgery, trauma, and optic nerve diseases. Axial length will be measured using optical biometry or A-scan ultrasonography, while the cup-to-disc ratio will be assessed through fundus examination using a slit lamp biomicroscope with a +90D lens or optical coherence tomography (OCT). Data will be meticulously documented, including patient demographics and medical history. The study will be completed within six months after approval, ensuring accurate and standardized measurements for reliable results.

Eligibility Criteria:
Inclusion Criteria:

* Male and female patients diagnosed with systemic hypertension for at least 1 year.
* Age between 18-70 years.
* Normal intraocular pressure (IOP\<-21mmhg)
* Axial length between 21mm and 26mm (to exclude extreme refractive errors)

Exclusion Criteria:

* History of glaucoma or ocular hypertension.
* High myopia (\<-6.00 D) or hyperopia (\>+6.00D).
* History of ocular surgery, trauma, or retinal diseases.
* Any optic nerve diseases.
Diagnostic Value of KL-6 in ILD

KL-6 may be a useful biomarker in patients with interstitial lung disease, but there is limited information in non-Asian populations. Therefore, it is necessary to carry out studies in other populations to confirm the diagnostic values of the biomarker and its prognostic implication.

Hypothesis KL-6 may be a useful biomarker in the management of interstitial lung diseases. But it is necessary to know more about its utility in the European population.

Study Objectives:

* To determine the concentration of KL-6 in serum of patients with pulmonary fibrosis at the time of diagnosis compared to patients without pulmonary fibrosis
* Diagnostic yield of KL-6 in patients with pulmonary fibrosis.
* Correlation of KL-6 values with functional and radiological parameters of disease severity at diagnosis.
* Correlation of serum KL-6 values with the evolution of the disease.


Eligibility Criteria:
Inclusion Criteria:

1. Subjects older than 18 years.
2. Chronic respiratory diseases )including Fibrotic interstitial lung disease, asthma or COPD) related or not to a connective tissue disease.
3. Acceptance of the patient to participate in the study by signing the informed consent after having discussed with the researchers the objectives, risks and potential benefits.

Exclusion Criteria:

1. Absence of informed consent
2. Psychiatric disorder or limitation of collaboration (including language, socio-cultural problem, etc.).
Efficacy and Safety of Young Health Plasma on Acute Stroke

Stroke is one of the main severe disease of public health importance. Recent studies showed that old age is one of the most important factors in influencing the outcome of patients with acute stroke, and the young plasma can reverse age-related brain impairments in mice. Therefore, this pilot study aims to investigate whether young plasma is effective in alleviating brain injury and neurologic deficits induced by acute stroke in patients.

This study will enroll 78 stroke patients who have been diagnosed with stroke and meet the inclusion criteria.

After successfully meeting initial screening criteria, investigators will contact the family, explain the study, and send a consent form for their review.

After that, patients will be given 2 unit/day young health plasma (young plasma exchange) over a course of 3 consecutive days, then investigators will make a neurofunctional assessment before and 7 days, 30 days and 90 days after young health plasma treatment. And Magnetic Resonance of the brain before, 7 days, 14 days and 90 days after young health plasma treatment.

Eligibility Criteria:
Inclusion Criteria:

* Age 65-80 years
* Clinical presentation of spontaneous intracerebral hemorrhage/ischemic stroke
* CT/MRI/MRA scan compatible with spontaneous intracerebral hemorrhage/ ischemic stroke
* Time to young plasma treatment \< 72 h from symptom onset
* Glasgow Coma Score \> 6 on initial presentation or improvement to a Glasgow Coma Score \> 6 within the time frame for enrollment
* The first-ever primary supratentorial intracerebral basal ganglia hemorrhage 5-30ml
* Signed and dated informed consent is obtained
* TOAST: Large-artery atherosclerosis

Exclusion Criteria:

* Patients who will undergo surgical evacuation of intracerebral hemorrhage/ischemic stroke
* Inability to undergo neuroimaging with Magnetic Resonance
* Glasgow Coma Score \< 6
* Significant past history of disability, modified Rankin Scale（mRS）≥1
* Primary intraventricular hemorrhage ICH due to coagulopathy (PT \> 15 s or International Normalized Ratio \> 1.3, Partial Thromboplastin Time \> 36) or trauma
* Thrombocytopenia: platelet count \<100 000
* Clinically significant hepatic disease as demonstrated by history, clinical exam (ascites, varices), or laboratory findings (LFTs \>2x normal, coagulopathy as described)
* Comorbid conditions likely to complicate therapy including but not limited to the following: a history of New York Heart Association class II, III, or IV Congestive Heart Failure; end-stage acquired immune deficiency syndrome
* Known pregnancy, or positive pregnancy test, or breast feeding
* Malignancy (history of or active)
* Bradyarrhythmia and Atrioventricular Block
* Concomitant use with antineoplastic,immunosuppressive or immune modulating therapies
* Macular Edema
* Life expectancy of less than 90 days due to comorbid conditions
* Occurrences of secondary intracerebral hemorrhage/ischemic stroke
* Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, noncompliance, living in another state or any other cause
A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers

The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-TTRSC (revusiran) in healthy volunteer subjects.


Eligibility Criteria:
Inclusion Criteria:

* Body mass index (BMI) must be ≥ 16.5 kg/m2 and ≤ 35.0 kg/m2;
* Female subjects must be of non-childbearing potential; e.g., postmenopausal or pre-menopausal with surgical sterilization;
* Male subjects agree to use appropriate contraception;
* Adequate blood counts, liver and renal function;
* Non-smokers for at least 3 months;
* Willing to give written informed consent and are willing to comply with the study requirements;
* Subject was born in Japan and has lived outside of Japan for \<10 years, and subject's biological parents and grandparents are fully Japanese and were born in Japan (cohorts 19 and 20).

Exclusion Criteria:

* Known human immunodeficiency virus (HIV) positive status or known or suspected systemic bacterial, viral, parasitic, or fungal infection;
* Subjects with a history of multiple drug allergies or intolerance to SC injection;
* History of drug abuse and/or alcohol abuse;
* Receiving an investigational agent within 3 months prior to study drug administration;
* Considered unfit for the study by the Principal Investigator.
Lens Wearing Experience and Biocompatibility of a Marketed Multi-Purpose Disinfecting Solution in Silicone Hydrogel and Soft Contact Lens Wearers

The purpose of this study was to describe mean differences in corneal staining (type and area) for OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS) at Day 30 compared to Baseline (Day 0).


Eligibility Criteria:
Inclusion Criteria:

* 18 years or older
* Soft contact lens wear on a daily wear basis
* Able to wear contact lenses for at least 8 hours
* Generally healthy and have normal ocular health
* Other protocol-defined inclusion criteria may apply

Exclusion Criteria:

* No use of additional lens cleaners
* No known sensitivities to any ingredient in the test article
* No history of ocular surgery/trauma within the last six months
* Other protocol-defined exclusion criteria may apply
Optical Transcutaneous Sensors of Capnia and Oxygenation

This study aims at validating new optical transcutaneous sensors to evaluate tissue capnia (CO2 partial pressure) and oxygenation (blood oxygen saturation) by comparing them to standard laboratory measurements (end tidal CO2 measurements and oxygen saturation by near-infrared spectroscopy).


Eligibility Criteria:
Inclusion Criteria:

* Males or females between 18 and 50 year old
* Individual having health insurance
* Individual able to provided informed consent
* Subjects with no known pathology and not taking any medical treatment a priori capable of interfering with controlled hypoxia at levels required in the protocol

Exclusion Criteria:

* Body mass index \>27 kg/m²
* History of acute mountain sickness
* Chronic diseases know to be associated with high methemoglobinemia
* Known allergy to one of the materials used in the devices (lycra, polyamide...), or to the adhesive plaster.
* Active smoker (\>3 cigarets/day)
* Alcohol consumption (\>10g/day)
* Individual with high skin sensitivity due to skin diseases
* Mental disorders
* Persons who refuse to sign the information sheet and participation agreement
* Persons under guardianship or not subject to a social security system
* Pregnant woman, parturient, breastfeeding mother
* Person deprived of liberty by judicial or administrative decision
* A person who is subject to a legal protection measure that cannot be included in clinical trials.
Using Media to Reduce Anxiety for Cardiac Computed Tomography

Coming for a cardiac test can be a daunting experience. Despite providing written information sheets for patients, experience in the scanner demonstrates that many patients are ill-prepared when they attend for cardiac computed tomography (CT). Heart rate control is essential for high image quality, as this prolongs cardiac diastole (during which imaging occurs) and results in less motion blur, but this may be challenging to achieve in the context of an anxious patient. In such situations, additional radiation exposure is required to optimise the chances of diagnostic images. Thus, poor patient selection and preparation has been shown to increase the radiation burden to the patient, as well as to increase the rate of non-diagnostic scans, leading to patients needing additional, alternative testing. This can be distressing for patients and increases downstream costs for the hospital. Poor patient awareness is also known to increase the anxiety of attending for a test.

Improved patient information and understanding has been shown to improve outcomes in a wide variety of hospital settings. Evidence from cardiac catheterisation angiography suggests that the use of alternative information formats can reduce patient anxiety and improve patient satisfaction, as well as improving their understanding of the technical requirements of a test. The latter may contribute to improved preparation - for example, patients who do not understand the requirements for cardiac CT, particularly the need for a slow heart rate, will often consume caffeine, stop their heart-slowing drugs, or even run or cycle to their appointment.

We have agreed a collaboration with Plymouth University to create patient information videos for CT. These will utilise the expertise of media students (their department also runs a commercial arm, due to the quality of their output), in conjunction with the clinical requirements and patient participation groups, to create an accessible, engaging and informative film. We wish to evaluate the impact of this method of conveying information to patients on how well they are prepared to undergo testing.

If this concept is successful, it may be of use to patients undergoing a huge range of tests or treatments across specialities. We therefore need to demonstrate the efficacy (or otherwise) of such an intervention.


Eligibility Criteria:
Inclusion Criteria:

* All adult patients over 18 years attending for CT coronary angiography during the trial period will be eligible for inclusion

Exclusion Criteria:

* Unable to provide valid, informed, written consent for any reason
* Attending for non-coronary cardiac CT
* Hospital inpatients
* Patients who have previously undergone cardiac CT
Bronchoscopy Screening for High-risk Population of Lung Cancer With Severe Smoking With Negative LDCT Screen

Based on the previous work of LDCT screening, in order to improve the screening rate of central lung cancer for LDCT negative and severe smokers, the investigators plan to conduct China's first large-scale fluorescent bronchoscopy screening test.

CT scan is a commonly used method for clinical screening for early lung cancer, but research shows that LDCT scan has a higher detection rate for peripheral lesions (often adenocarcinoma), and a lower detection rate for central lung cancer (mostly squamous cell carcinoma). Fluorescent bronchoscopy uses the principle of differentiating fluorescence in different tissues to distinguish normal parts from diseased parts. It is often used for screening of central early lung cancer.Based on the results of the investigator's previous research, the investigators plan to conduct a second round of community screening-bronchoscopy screening, and perform white light bronchoscopy and autofluorescence bronchoscopy screening for high-risk groups of lung cancer with heavy smoking (≥400 years) and no obvious lung nodules.

Eligibility Criteria:
Inclusion Criteria:

1. Age 45-75 years;
2. have a smoking history of ≥20 pack years; if participants quit smoking, it should be \<15 years;
3. Chest LDCT examination within one and a half years without obvious abnormalities or calcified nodules or non-calcified nodules and no signs of malignancy

Exclusion Criteria:

1. Non-smokers or mild smokers;
2. There are contraindications to bronchoscopy, such as active hemoptysis, unstable angina pectoris, coagulation dysfunction, anesthesia allergy, etc .;
3. Refusing to sign informed consent;
4. The operator believes that the patient has other conditions that are not suitable for bronchoscopy.
Early Prone Position on Coronavirus Disease 2019 Pneumonia

the purpose of this study to evaluate the effect of early awake PP (prone position)application on oxygenation and intubation requirement in patients with acute respiratory failure due to coronavirus disease 2019 pneumonia.

The first group (early prone position-EPP) created for our study was composed of patients who received PP at least 12 hours early (with the first 48 hours) with the oxygen support of the reservoir mask, and the second group (non-EPP ) patients who received oxygen with the reservoir mask but could not be applied early PP due to the patient's incompatibility or rejection.

Conventional oxygen therapy applied to all patients was given with a reservoir mask, aiming at oxygen saturation 93% and above, at a flow rate of 6-15 L / min.

Despite all the treatments, the patients who have a follow-up with a respiratory acidosis , oxygen saturation value below 93%, applied non invasive mechanical ventilation, in case of insufficient patient intubated and have invasive mechanical ventilation. In patients who had regression of glasgow coma scale during follow-up, orotracheal intubation was performed and invasive mechanical ventilation was performed.

Eligibility Criteria:
Inclusion Criteria:

* Patients who developed acute respiratory failure due to coronavirus disease 2019 pneumonia
* received conventional oxygen therapy with reservoir mask oxygen at the stage of admission to the intensive care unit
* older than 18 years old

Exclusion Criteria:

* patients with respiratory acidosis,
* partial oxygen pressure/fraction of inspired oxygen ratio below 150,
* Glasgow Coma Score (GKS) below 12 points,
* hemodynamic instability,
* primary pulmonary pathologies other than pneumonia (lung cancer, cardiopulmonary edema, carcinogen syndrome, etc.)
* patients who underwent non-invasive mechanical ventilation(NIMV) or intubated from admission to intensive care,
* those who underwent self prone position under 12 hours were not included in the study.
Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease

This early phase I trial studies how well fluciclovine F18 positron emission tomography (PET)/computed tomography (CT) works in identifying the origin of head and neck squamous cell carcinoma in patients with cancer that has spread to the cervical lymph nodes. Fluciclovine F18 during a PET/CT scan may work better in helping doctors learn where the cancer started (called the site of origin) and directing treatment planning compared to standard fludeoxyglucose F-18 (FDG) PET-CT scans.

PRIMARY OBJECTIVES:

I. To estimate positive predictive value with a corresponding 95% confidence interval for fluciclovine F18 (18F fluciclovine) positron emission tomography computed tomography (PET CT) to detect a primary site of disease in patients presenting with cervical metastatic nodal disease but a head and neck primary site not apparent on CT of the neck with contrast (contrast enhanced-computed tomography, CE-CT).

SECONDARY OBJECTIVES:

I. To estimate positive predictive value with a corresponding 95% confidence interval for fludeoxyglucose F-18 (18F FDG) PET CT in the detection of a primary site of disease in patients presenting with cervical metastatic nodal disease but a head and neck primary site not apparent on CT of the neck with contrast.

EXPLORATORY OBJECTIVES:

I. To compare the lesion to background (L/B) ratios for nodal metastatic disease between 18F fluciclovine PET CT and 18F FDG PET CT.

II. To estimate the sensitivity of 18F fluciclovine PET CT and 18F FDG PET CT to detect nodal disease.

III. To evaluate for any trends in findings on 18F fluciclovine PET CT and human papillomavirus (HPV) status.

OUTLINE:

Patients receive fluciclovine F18 intravenously (IV) and undergo PET/CT scan over 20-30 minutes.

Eligibility Criteria:
Inclusion Criteria:

* Adults with biopsy proven metastatic cervical nodal squamous cell carcinoma
* CT of the neck with contrast that does not confidently identify a primary oropharyngeal site of disease
* Planned standard of care 18F-FDG PET CT examination
* Planned standard of care exam under anesthesia with oropharyngeal surgical biopsy

Exclusion Criteria:

* Pregnant women
* Known allergy to FDG, fluciclovine, or iodine-based contrast agents
* Severe renal dysfunction (glomerular filtrate rate \[within 30 days\] less than 30)
* Inability to tolerate lying supine, relatively motionless for up to 1 hour
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis

The purpose of this study is to learn more about the role of etanercept alone or in combination with methotrexate on disease activity in adults with psoriatic arthritis.

The study will consist of a 30-day screening period, a 48-week double-blind treatment period and a 30-day safety follow-up period.

At or after week 24, participants with an inadequate response could receive rescue therapy with etanercept plus methotrexate until the end of the treatment period.

Eligibility Criteria:
Key Inclusion Criteria:

* Subject must have a diagnosis of psoriatic arthritis (PsA) by the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria.
* Subject has ≥ 3 tender and ≥ 3 swollen joints at screening and at baseline.
* Subject has an active psoriatic skin lesion
* Subject is naïve to etanercept and any other biologic for the treatment for PsA or psoriasis.
* Subject has no prior use of methotrexate for PsA.
* Subject has no history of tuberculosis
* Subject has a negative test for tuberculosis, hepatitis B and C.

Exclusion Criteria:

* Subject has known history of alcoholic hepatitis, nonalcoholic steatohepatitis or immunodeficiency syndromes, including human immunodeficiency virus (HIV) infection.
* Subject has any active infection (including chronic or localized infections) for which anti-infectives were indicated within 4 weeks prior to the first dose of investigational product.
* Subject has a serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to the first dose of investigational product.
Quantification of Upper Extremity Hypertonia

Dr. Sanger and the research team want to learn about upper extremity hypertonia (stiffness) in children and young adults with cerebral palsy. Specifically, they want to learn about ways to measure the stiffness in the joints of hypertonic arms. The information the research team will collect includes any physical exams or computer generated data about your arm movements.


Eligibility Criteria:
Inclusion Criteria:Dystonia in at least one arm Age 4 to no upper limit

Exclusion Criteria:increased risk of participation botulinum toxin within 6 months